Inspira Technologies Oxy BHN Ltd
NASDAQ:IINN

  • LAST PRICE
    1.3600
  • TODAY'S CHANGE (%)
    0.0100 (0.7407%)
  • Bid / Lots
    1.3600/ 2
  • Ask / Lots
    1.4200/ 50
  • Open / Previous Close
    1.3700 / 1.3500
  • Day Range
    1.3400
    1.3800
  • 52 Week Range
    0.7613
    2.4900
  • Volume
    174,999

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 8, 2024

  • Oct 25, 2024

  • Oct 24, 2024

      Show headlines and story abstract

    • 12:17PM ET on Thursday Oct 24, 2024 by PR Newswire
      Companies Mentioned: IINN

      In the news release, Inspira™ Announces Establishment of Distribution Facility to Support U.S. Deployment of INSPIRA™ ART100, issued 24-Oct-2024 by Inspira Technologies over PR Newswire, we are advised by the company that the first paragraph, should read "Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, is pleased to announce that it has entered into an agreement with Glo-Med Networks Inc ("Glo-Med"), which will serve as Inspira's primary distributor in the United States. Glo-Med's distribution facility will serve as a support center for the deployment of the INSPIRA ART100 in the United States. The INSPIRA ART100 is U.S. Food and Drug Administration (FDA) 510(k)-cleared for Cardiopulmonary Bypass (CPB) procedures." rather than "Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, is pleased to announce that it has entered into an agreement with Glo-Med Networks Inc ("Glo-Med"), which will serve as Inspira's primary distributor in the United States. Glo-Med's distribution facility will serve as a support center for the deployment of the INSPIRA ART100 in the United States. The INSPIRA ART100 is U.S. Food and Drug Administration (FDA) 510(k)-cleared for Cardiopulmonary Bypass (CPB) procedures.Inspira aims to revolutionize life support for millions of acute respiratory failure patients each year with the Company's proprietary INSPIRA™ ART device being designed to monitor and elevate declining blood saturation levels in minutes without a mechanical ventilator. Targeting 20 million patients each year, the INSPIRA ART has a potential estimated $19 billion market opportunity. This agreement and distribution facility aims to enhance the Company's operational efficiency and customer service capabilities in the U.S. market. Toward the planned deployment of the INSPIRA ART100 in 2024 and looking ahead, the Company's goal is to introduce physicians and perfusionists to Inspira's technologies and brand proposition in preparation for the future planned deployment of the flagship INSPIRA ART." as originally issued inadvertently. The complete, corrected release follows:

Peers Headlines